This Billionaire is Buying These 5 Bargain Stocks Amid Selloff

3. Affimed N.V. (NASDAQ:AFMD)

Number of Hedge Fund Holders: 16

YTD Share Price Decline as of May 26: 43.10%

Affimed N.V. (NASDAQ:AFMD) is a German clinical-stage biopharmaceutical company, focused on developing cancer immunotherapies in the United States, Germany, and the rest of Europe. Paul Tudor Jones added Affimed N.V. (NASDAQ:AFMD) to his Q1 portfolio by acquiring 14,693 shares worth $64,000. Year-to-date, Affimed N.V. (NASDAQ:AFMD) stock has dropped over 43% as of May 26. 

On April 11, Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and a $12 price target on Affimed N.V. (NASDAQ:AFMD), stating that the stock remains one of the firm’s top ideas for 2022. The analyst believes the updated data of AFM13 + NK combination lends robust support to the best-case scenario.

The Q1 database of Insider Monkey suggests that 16 hedge funds were long Affimed N.V. (NASDAQ:AFMD), up from 13 funds in the preceding quarter. Steve Cohen’s Point72 Asset Management is the largest stakeholder of the company, with 9.3 million shares valued at about $41 million.